Edition:
United Kingdom

Galapagos NV (GLPG.OQ)

GLPG.OQ on NASDAQ Stock Exchange Global Select Market

100.15USD
7 Dec 2018
Change (% chg)

$-1.10 (-1.09%)
Prev Close
$101.25
Open
$103.01
Day's High
$103.68
Day's Low
$100.15
Volume
35,879
Avg. Vol
45,479
52-wk High
$122.28
52-wk Low
$84.15

Latest Key Developments (Source: Significant Developments)

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

REFILE-Vertex posts positive data from cystic fibrosis triple combo trials

Nov 27 Vertex Pharmaceuticals Inc said on Tuesday that its triple combination therapy showed significant improvement in lung function in patients with cystic fibrosis (CF) in two late-stage clinical studies, sending its shares up 5 percent.